As an alternative strategy to target IGF signaling, results of phase 1 clinical trials of the dual IGF1/2-neutralizing antibodies have been reported, while no results of phase 2/3 trials in cancer therapy have been reported [156, 157]. The gene discussed is IGF1; the disease is cancer.